This trial is active, not recruiting.

Conditions rheumatoid arthritis, depression, anxiety
Sponsor University of Pavia
Start date January 2014
End date December 2015
Trial size 300 participants
Trial identifier NCT02122406, 31748\2009 progetto lorhen


The primary endpoint of this study is to evaluate the prevalence of anxiety and depressive disorders, and their relationship with disease activity, in patients with rheumatoid arthritis treated with biological drugs

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective cross-sectional
Patients with rheumatoid arthritis treated with biological drugs

Primary Outcomes

Disease Activity Score 28
time frame: 1 day of enrollement
Hospital Anxiety and Depression Scale (HADS)
time frame: 1 day of enrollement

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - age >18 years - diagnosis of rheumatoid arthritis according to 2010 Classification American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Criteria - being able to compile questionnaire - current treatment with biological disease-modifying antirheumatic drug Exclusion Criteria: - Current treatment for anxiety or depressive disorder

Additional Information

Official title Depression and Anxiety in Rheumatoid Arthritis: Prevalence and Relation With Disease Activity
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by University of Pavia.